International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14679 - 14679
Опубликована: Сен. 28, 2023
In
the
last
few
decades,
RNA-based
drugs
have
emerged
as
a
promising
candidate
in
treatment
of
various
diseases.
The
introduction
messenger
RNA
(mRNA)
vaccine
or
therapeutic
agent
enables
production
almost
any
functional
protein/peptide.
key
to
applying
therapy
clinical
trials
is
developing
safe
and
effective
delivery
systems.
Exosomes
lipid
nanoparticles
(LNPs)
been
exploited
vehicles
for
drug
delivery.
This
review
discusses
feasibility
exosomes
LNPs
mRNA
Cancer/testis
antigens
(CTAs)
show
restricted
expression
normal
tissues
widespread
cancer
tissues.
Many
these
CTAs
sera
patients
with
cancers.
These
characteristics
make
them
excellent
targets
immunotherapy.
summarizes
roles
life
processes
current
studies
on
mRNAs
encoding
CTAs.
Clinical
present
beneficial
effects
highlight
employing
mRNA-LNPs
Pharmaceutics,
Год журнала:
2023,
Номер
15(7), С. 1972 - 1972
Опубликована: Июль 18, 2023
Messenger
RNA
(mRNA)
vaccine
development
for
preventive
and
therapeutic
applications
has
evolved
rapidly
over
the
last
decade.
The
mRVNA
proven
efficacy
in
various
applications,
including
infectious
disease,
immunotherapy,
genetic
disorders,
regenerative
medicine,
cancer.
Many
mRNA
vaccines
have
made
it
to
clinical
trials,
a
couple
obtained
FDA
approval.
This
emerging
approach
several
advantages
conventional
methods:
safety;
efficacy;
adaptability;
bulk
production;
cost-effectiveness.
However,
is
worth
mentioning
that
delivery
target
site
vivo
degradation
thermal
stability
are
boundaries
can
alter
their
outcomes.
In
this
review,
we
shed
light
on
different
types
of
vaccines,
mode
action,
process
optimize
overcome
limitations.
We
also
explored
systems
focusing
nanoparticle-mediated
vaccine.
Generally,
system
plays
vital
role
enhancing
stability,
biocompatibility,
homing
desired
cells
tissues.
addition
function
as
vehicle,
they
serve
compartment
shields
protects
molecules
against
physical,
chemical,
biological
activities
efficiency.
Finally,
focused
future
considerations
should
be
attained
safer
more
efficient
application
underlining
disadvantages
current
vaccines.
Vaccines,
Год журнала:
2024,
Номер
12(2), С. 186 - 186
Опубликована: Фев. 12, 2024
In
recent
years,
lipid
nanoparticles
(LNPs)
have
attracted
extensive
attention
in
tumor
immunotherapy.
Targeting
immune
cells
cancer
therapy
has
become
a
strategy
of
great
research
interest.
mRNA
vaccines
are
potential
choice
for
immunotherapy,
due
to
their
ability
directly
encode
antigen
proteins
and
stimulate
strong
response.
However,
the
mode
delivery
lack
stability
key
issues
limiting
its
application.
LNPs
an
excellent
carrier,
structural
biocompatibility
make
them
effective
means
delivering
specific
targets.
This
study
summarizes
progress
LNP
carrier-assisted
targeted
controlled
release
immunity.
The
role
improving
stability,
immunogenicity,
targeting
is
discussed.
review
aims
systematically
summarize
latest
immunity
provide
new
ideas
strategies
as
well
more
treatment
plans
patients.
Biomedicines,
Год журнала:
2024,
Номер
12(1), С. 123 - 123
Опубликована: Янв. 7, 2024
Lung
cancer
demands
innovative
approaches
for
early
detection
and
targeted
treatment.
In
addressing
this
urgent
need,
exosomes
play
a
pivotal
role
in
revolutionizing
both
the
treatment
of
lung
cancer.
Their
remarkable
capacity
to
encapsulate
diverse
range
biomolecules,
traverse
biological
barriers,
be
engineered
with
specific
targeting
molecules
makes
them
highly
promising
diagnostic
markers
precise
drug
delivery
cells.
Furthermore,
an
in-depth
analysis
exosomal
content
biogenesis
offers
crucial
insights
into
molecular
profile
tumors.
This
knowledge
holds
significant
potential
development
therapies
strategies
Despite
notable
progress
field,
challenges
standardization
cargo
loading
persist.
Collaborative
research
efforts
are
imperative
maximize
advance
field
precision
medicine
benefit
patients.
Beilstein Journal of Nanotechnology,
Год журнала:
2024,
Номер
15, С. 333 - 349
Опубликована: Март 27, 2024
Chagas
disease
(CD)
is
the
most
important
endemic
parasitosis
in
South
America
and
represents
a
great
socioeconomic
burden
for
chronically
ill
their
families.
The
only
currently
available
treatment
against
CD
based
on
oral
administration
of
benznidazole,
an
agent,
developed
1971,
controversial
effectiveness
patients
toxic
to
adults.
So
far,
conventional
pharmacological
approaches
have
failed
offer
more
effective
less
alternatives
benznidazole.
Nanomedicines
reduce
toxicity
increase
current
oncological
therapies.
Could
nanomedicines
improve
neglected
CD?
This
question
will
be
addressed
this
review,
first
by
critically
discussing
selected
reports
performance
benznidazole
other
molecules
formulated
as
vitro
vivo
models.
Taking
into
consideration
developmental
barriers
degree
technical
preclinical
efforts,
prospect
developing
provided.
Not
surprisingly,
we
conclude
that
structurally
simpler
formulations
with
minimal
production
cost,
such
nanocrystals
and/or
parenteral
nano-immunostimulants,
highest
chances
making
it
market
treat
CD.
Nonetheless,
substantive
political
economic
decisions,
key
facing
technological
challenges,
are
still
required
regarding
realistic
use
Abstract
Due
to
the
outbreak
of
novel
coronavirus
pneumonia,
messenger
RNA
(mRNA)
technology
has
attracted
heated
attention.
A
specific,
safe,
and
efficient
mRNA
delivery
system
is
needed.
Lipid
nanocarriers
have
become
attractive
carriers
for
due
their
high
efficiency,
few
side
effects,
easy
modification
change
structures
functions.
To
achieve
desired
biological
effect,
lipid
must
reach
designated
location
effective
drug
delivery.
Therefore,
effects
composition
on
key
properties
are
briefly
reviewed.
In
addition,
progress
smart
by
changing
summarized,
importance
component
design
structure
emphasized.
Subsequently,
this
review
summarizes
latest
in
nanocarrier‐based
provides
corresponding
strategies
its
current
challenges,
putting
forward
valuable
information
future
mRNA.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Март 12, 2024
Background
The
implementation
of
mRNA
vaccines
against
COVID-19
has
successfully
validated
the
safety
and
efficacy
platform,
while
at
same
time
revealing
potential
for
their
applications
other
infectious
diseases.
Traditional
seasonal
influenza
often
induce
strain
specific
antibody
responses
that
offer
limited
protection
antigenically
drifted
viruses,
leading
to
reduced
vaccine
efficacy.
Modern
advances
in
viral
surveillance
sequencing
have
led
development
in-silico
methodologies
generating
computationally
optimized
broadly
reactive
antigens
(COBRAs)
improve
vaccines.
Methods
In
this
study,
immunologically
naïve
mice
were
intramuscularly
vaccinated
with
encoding
H1
H3
COBRA
hemagglutinins
(HA)
or
wild-type
(WT)
HAs
encapsulated
lipid
nanoparticles
(LNPs).
Results
Mice
HA-encoding
generated
robust
neutralizing
serum
more
distinct
contemporary
future
H1N1
H3N2
strains
than
those
WT
also
prevented
illness,
including
severe
disease
mouse
model
viruses.
Conclusions
This
study
highlights
benefits
combining
universal
antigen
design
technology
modern
delivery
platforms
exhibits
how
these
can
be
advantageous
over
traditional
eliciting
superior
protective
a
broader
number
virus
isolates.
International Journal of Pharmaceutics,
Год журнала:
2024,
Номер
663, С. 124545 - 124545
Опубликована: Авг. 3, 2024
Cancers
are
increasing
in
prevalence
and
many
challenges
remain
for
their
treatment,
such
as
chemoresistance
toxicity.
In
this
context,
siRNA-based
therapeutics
have
potential
advantages
cancer
therapies
a
result
of
ability
to
reduce
or
prevent
expression
specific
cancer-related
genes.
However,
the
direct
delivery
naked
siRNA
is
hindered
by
issues
like
enzymatic
degradation,
insufficient
cellular
uptake,
poor
pharmacokinetics.
Hence,
discovery
safe
efficient
vehicle
essential.
This
review
explores
various
lipid
polymer-based
systems
treatment.
Both
polymers
lipids
garnered
considerable
attention
carriers
delivery.
While
all
these
protect
enhance
transfection
efficacy,
each
exhibits
its
unique
strengths.
Lipid-based
systems,
instance,
demonstrate
high
entrapment
efficacy
utilize
cost-effective
materials.
Conversely,
polymeric-based
offer
through
chemical
modifications.
Nonetheless,
certain
drawbacks
still
limit
usage.
To
address
limitations,
combining
different
materials
formulations
(lipid,
polymer,
targeting
agent)
could
pharmaceutical
properties,
boost
side
effects.
Furthermore,
co-delivery
with
other
therapeutic
agents
presents
promising
strategy
overcome
resistance.
been
demonstrated
encapsulate
efficiency,
but
most
limited
terms
functionalities
they
display.
contrast,
can
be
chemically
modified
wide
variety
routes
include
multiple
components,
release
elements,
from
same
backbone.
Accordingly,
incorporating
lipids,
polymers,
and/or
RNA
it
possible
improve
properties
while
reducing
focuses
on
strategies
treatments
discusses
future
prospects
important
field.
